Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.51 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.51 |
| ▸ | PPARG | P37231 | 1/20 | 0.51 |
| ▸ | NCOA2 | Q15596 | 1/20 | 0.51 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.51 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.51 |
| ▸ | HPGD | P15428 | 5/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | ATM | Q13315 | 1/20 | 0.50 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.50 |
| ▸ | PARP1 | P09874 | 1/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | RAF1 | P04049 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.41 |
| ▸ | MAPT | P10636 | 4/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.38 |
| ▸ | NPC1 | O15118 | 2/20 | 0.38 |
| ▸ | RAB9A | P51151 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL317871 | 0.86 | HPGD (0.55) | LMNANPSR1PPARGNCOA2NCOA1 | |
| SCHEMBL7613895 | 0.86 | LMNA (0.49) | LMNANPSR1PPARGNCOA2NCOA1 | |
| SCHEMBL6978193 | 0.84 | HPGD (0.59) | LMNANPSR1PPARGNCOA2NCOA1 | |
| SCHEMBL1401544 | 0.83 | LMNA (0.53) | LMNANPSR1PPARGNCOA2NCOA1 | |
| SCHEMBL11984343 | 0.83 | HPGD (0.56) | LMNANPSR1PPARGNCOA2NCOA1 | |
| SCHEMBL6848383 | 0.82 | HDAC3 (0.55) | HPGDL3MBTL1TSHRMAPK1ALDH1A1 | |
| SCHEMBL14135378 | 0.81 | LMNA (0.51) | LMNANPSR1PPARGNCOA2NCOA1 | |
| SCHEMBL1977403 | 0.81 | NPSR1 (0.51) | LMNANPSR1PPARGNCOA2NCOA1 | |
| SCHEMBL28857673 | 0.81 | LMNA (0.51) | LMNANPSR1PPARGNCOA2NCOA1 | |
| SCHEMBL14114132 | 0.81 | LMNA (0.51) | LMNANPSR1PPARGNCOA2NCOA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 262 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260049078-A1 | DIFLUORO- AND TRIFLUORO-ACETYL HYDRAZIDES AS SELECTIVE HDAC6 INHIBITORS | ITALFARMACO SPA (IT) | 2026-02-19 | — | — | US | disclosed |
| EP-4558494-A1 | 1,3,4-OXADIAZOLE DERIVATIVES AS SELECTIVE HISTONE DEACETYLASE 6 INHIBITORS | ITALFARMACO S.p.A. (IT) | 2025-05-28 | — | — | EP | disclosed |
| US-20250129077-A1 | SUBSTITUTED PURINES AS TLR7 AGONISTS | Primmune Therapeutics, Inc. | 2025-04-24 | — | — | US | disclosed |
| EP-4512816-A2 | TLR7 AGONISTS | Primmune Therapeutics, Inc. (US) | 2025-02-26 | — | — | EP | disclosed |
| CN-112533607-B | TLR7 agonists | 普利缪尼治疗学股份有限公司 | 2025-01-07 | — | — | CN | disclosed |
| EP-3801538-B1 | TLR7 AGONISTS | PRIMMUNE THERAPEUTICS INC (US) | 2024-10-02 | — | — | EP | disclosed |
| CN-116283817-B | NO donor type HDAC inhibitor, composition and application thereof | 安徽中医药大学 | 2024-08-02 | — | — | CN | disclosed |
| US-12037335-B2 | Substituted purines as TLR7 agonists | Primmune Therapeutics, Inc. (US) | 2024-07-16 | — | — | US | disclosed |
| US-12017997-B2 | Host-targeted pan-respiratory antiviral small molecule therapeutics | PROSETTA BIOSCIENCES, INC. (US) | 2024-06-25 | — | — | US | disclosed |
| CN-117736192-A | PI3K/HDAC dual inhibitor and application thereof | 安徽中医药大学 | 2024-03-22 | — | — | CN | disclosed |
| EP-0532674-A4 | LEUKOTRIENE ANTAGONISTS | — | 1993-04-07 | — | — | EP | disclosed |
| EP-0534667-A1 | Tricyclic heterocycles as PGE2 antagonists | ZENECA LIMITED (GB) | 1993-03-31 | — | — | EP | disclosed |
| EP-0532674-A1 | LEUKOTRIENE ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 1993-03-24 | — | — | EP | disclosed |
| WO-1992020651-A2 | N-(HETEROARYL)-IMIDAZOLYL-ALKENOIC ACIDS | SMITHKLINE BEECHAM CORPORATION (US) | 1992-11-26 | — | — | WO | disclosed |
| WO-1991018889-A1 | LEUKOTRIENE ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 1991-12-12 | — | — | WO | disclosed |
| US-4837316-A | ANTIULCER AGENTS | FUJIREBIO KABUSHIKI KAISHA (JP) | 1989-06-06 | — | — | US | disclosed |
| EP-0214823-A2 | Alkylamide derivatives with H2-receptor antagonistic and cytoprotective action | FUJIREBIO KABUSHIKI KAISHA also trading as FUJIREBIO INC. (JP) | 1987-03-18 | — | — | EP | disclosed |
| US-4122256-A | OPTICAL BRIGHTENERS | HOECHST AKTIENGESELLSCHAFT (DE) | 1978-10-24 | — | — | US | disclosed |
| US-4052433-A | INTERMEDIATES FOR BENZOFURANS | HOECHST AKTIENGESELLSCHAFT (DT) | 1977-10-04 | — | — | US | disclosed |
| US-3994879-A | CONDENSING AZOMETHINES, OPTICAL BRIGHTENERS | HOECHST AKTIENGESELLSCHAFT (DT) | 1976-11-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12017997-B2 | Host-targeted pan-respiratory antiviral small molecule therapeutics | MAVS, SARS1, ZC3HAV1 | LMNA 2763/4885NPSR1 2167/4885PPARG 1424/4885 |
| US-12037335-B2 | Substituted purines as TLR7 agonists | TLR7, TLR9, TLR1 | LMNA 2179/4885NPSR1 816/4885PPARG 242/4885 |
| US-20260049078-A1 | DIFLUORO- AND TRIFLUORO-ACETYL HYDRAZIDES AS SELECTIVE HDAC6 INHIBITORS | HDAC3, HDAC1, HDAC6 | LMNA 2016/4885NPSR1 1748/4885PPARG 653/4885 |
| US-20250129077-A1 | SUBSTITUTED PURINES AS TLR7 AGONISTS | TLR7, TLR9, TLR1 | LMNA 2179/4885NPSR1 816/4885PPARG 242/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.